UBS AM
VIRX

UBS AM’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

UBS AM’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,829
Closed -$941K – 2727
2015
Q1 		$941K Sell
1,829
-2,229
-55% -$1.12M ﹤0.01% 1661
2014
Q4 		$2.17M Buy
4,058
+1,429
+54% +$644K ﹤0.01% 1289
2014
Q3 		$3.94M Sell
2,629
-1,681
-39% -$2.43M ﹤0.01% 1084
2014
Q2 		$5.9M Buy
4,310
+519
+14% +$602K 0.01% 994
2014
Q1 		$5.26M Buy
3,791
+913
+32% +$1.06M 0.01% 1028
2013
Q4 		$2.86M Hold
2,878
– – ﹤0.01% 1145
2013
Q3 		$3M Hold
2,878
– – ﹤0.01% 1105
2013
Q2 		$3.15M Buy
+2,878
New +$3.21M ﹤0.01% 1073

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS AM's VIRX Position: Q2 2015 in Review

UBS AM sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2015, closing a stake of 1,829 shares — an estimated $941K sold.

UBS AM first reported a position in VIRX in Q2 2013 and held it in 8 quarters. The position peaked at $5.9M in Q2 2014. 80 funds tracked by Wall St. Rank hold VIRX as of Q2 2015.

  • UBS AM reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • UBS AM sold 1,829 Viracta Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $941K.
  • UBS AM first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 8 quarters.
  • UBS AM's Viracta Therapeutics, Inc. Common Stock position peaked at $5.9M in Q2 2014.
  • 80 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2015.

Based on UBS AM's 13F filing for Q2 2015, filed 12 Aug 2015.